Hutch News
Results per Page:
Promising results in trial of engineered T cells in high-risk leukemia
High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia
What's new in blood diseases
Four things to watch from the 2016 annual meeting of the American Society of Hematology
The quest to better understand the deadliest childhood leukemia
Oncologists are beginning to leverage unique genomic characteristics of pediatric AML to improve treatment and prognosis
Immunotherapy shows promise in preventing leukemia relapse
Group of 12 high-risk patients who received engineered T cells after bone marrow transplant still in remission
Immunotherapy shows promise in preventing leukemia relapse
Group of 12 high-risk patients who received engineered T cells after bone marrow transplant still in remission after more than two years
Sorting stem cells before transplant helps lower risk of graft-vs.-host disease, researcher reports at ASH
Sorting stem cells before transplant helps lower the risk of graft-vs.-host disease, researcher reports
Three's a charm in a triple-drug combination for transplant patients
A drug with a storied past offers a new edge against an old foe
‘Can’t sit and wait’: Gene therapy trial aims to cure rare Fanconi anemia
At annual hematology meeting, Fred Hutch researchers updated their treatment of 11-year-old Behzad
CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL
Results of early-phase trial of patients with chronic lymphocytic leukemia will be presented by Fred Hutch researchers at the American Society of Hematology Annual Meeting and Exposition
Fred Hutch research to be presented at American Society of Hematology conference
Fred Hutch researchers to share latest research in immunotherapy, genetic markers, graft vs. host disease, cord blood and more
New approach aims to restore immune-powering B cells in cancer patients following successful immunotherapy with CAR T cells
New approach, not yet tested in humans, aims to restore immune-powering B cells in cancer patients following successful CAR T-cell therapy
Umbilical cord blood transplant linked to lower relapse in high-risk leukemia patients
Study compares ‘alternative’ donor source vs. traditional transplantation of blood stem cells from an adult, unrelated donor
Patients with advanced lymphoma in remission after T-cell therapy
New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission